Pneumonia Testing Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, China, Japan, Germany, UK - Size and Forecast 2023-2027

Pneumonia Testing Market Forecast 2023-2027

The pneumonia testing market size is forecast to increase by USD 709 million, at a CAGR of 5.3% between 2022 and 2027. Market expansion is driven by various factors, including the rising prevalence of pneumonia and heightened mortality concerns related to the disease, advancements in multiplex PCR technology facilitating pneumonia detection, and the expanding elderly population. Nevertheless, challenges like insufficient healthcare infrastructure in developing countries, a scarcity of skilled workforce, and stringent governmental regulations pose obstacles to market growth.

What will be the size of the Market During the Forecast Period?

To learn more about this report, Download  Market Research Report Sample PDF

The market for pneumonics tests is competitive, with key players including Thermo Fisher Scientific, bioMérieux, and Roche Diagnostics. These companies offer a range of diagnostic tests, including NATs, culture-based tests, and rapid diagnostic tests. The market is also witnessing the development of new technologies, such as artificial intelligence and machine learning, which are expected to revolutionize pneumonia diagnosis and treatment. In conclusion, the pneumonics testing market is a critical segment of the healthcare industry, providing essential diagnostic tools for identifying and treating pneumonia. The market is growing due to the increasing prevalence of pneumonia and the need for accurate and timely diagnosis. 

Market Segmentation

The Pneumonics market encompasses various diagnostic tests used to identify and treat pneumonic conditions. Antibiotics are commonly prescribed based on the results of these tests. Nucleic acid tests (NATs) and culture-based tests are two primary methods used for pneumonia diagnosis. Pneumonics tests play a crucial role in identifying the causative organisms and determining the most effective treatment. Pneumonics tests are essential in healthcare settings, particularly in hospitals and clinics. The market for these tests is growing due to the increasing prevalence of pneumonia and the need for accurate and timely diagnosis. The use of point-of-care tests and rapid diagnostic tests is increasing, enabling healthcare professionals to make quicker and more informed decisions. 

By Product Type

The market share growth by the consumables segment will be significant during the forecast period. The consumables used for the detection of pneumonia contamination include kits and reagents such as PCR assays, nucleic acid detection kits, staining materials, elimination kits and reagents, standards, and controls.

Get a glance at the market contribution of various segments Request Market Research Report Sample PDF

The consumables segment was valued at USD 1.07 billion in 2017 and continued to grow until 2021. Industry encompasses diagnostic methods for identifying microbial pathogens causing pneumonia. Immunodiagnostics, utilizing antibodies and antigens, plays a significant role, offering advantages such as high sensitivity and specificity. Key applications include infectious diseases in children and geriatric populations. Nucleic acid detection methods, like Polymerase Chain Reaction (PCR), are also essential. Antibiotics and antifungals treatment relies on accurate diagnostics.

Healthcare expenditure and infrastructure development are influenced by pneumonia diagnostics, with reimbursements aiding market growth. Traditional methods, like cultures, face challenges due to their time-consuming process and error rate. Major players include Curetis, GE Healthcare, and Thoracic Care Suite. Immunofluorescence and Point-of-Care (POC) testing are gaining popularity. The forecast period sees continued growth due to sedentary lifestyles, unhealthy food habits, and environmental factors contributing to the prevalence of pneumonia. Early detection is crucial for effective medical condition management. The Streptococcus-based segment dominates, with Streptococcus pneumoniae being a common microbial pathogen. Morbidity and fatality rates underscore the importance of accurate diagnostics. Molecular diagnostic assays and the microbiome are emerging areas of interest. Guidelines from organizations like the American Thoracic Society (ATS), Infectious Diseases Society of America (IDSA), and CAP further emphasize the need for advanced diagnostics.
a. Hence, the increasing focus of companies on developing consumables such as kits and reagents used for detection and the adoption of these consumables by various end-users are expected to positively impact the growth of the market during the forecast period. 

Regional Analysis

For more insights on the market share of various regions Request Market Research Report Sample PDF

North America is estimated to contribute 32% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional market trends and analysis and drivers that shape the market during the forecast period. North America is a dominating region in the global market, with the US and Canada as the leading revenue-generating countries. Increasing demand for timely and accurate diagnosis of lung infections and other infectious diseases and the presence of several pharmaceutical companies that are focusing on drug development is driving the adoption of testing in the region. Moreover, several big pharmaceutical companies, such as bioMerieux, Pfizer, Roche, and several others, are researching to develop drugs and produce vaccines, which, in turn, has increased the demand for tests for drug screening and other purposes. For instance, in 2021, Pfizer announced to receive approval from FDA for PREVNAR, 20 Pfizer's pneumococcal 20-valent conjugate vaccine for adults ages 18 years or older. Such developments and approvals are expected to drive the market growth of the regional market during the forecast period.

In addition, R&D investments have increased in the region.  This resulted in the increased production of pharmaceutical products such as drugs, vaccines, and antibodies for the treatment of people suffering from various diseases, in turn, increasing the demand for tests to monitor the production of such products. Furthermore, the pharmaceutical industry is growing in the region due to the need for drug discovery and is expected to reach USD 1 trillion by the end of 2023 due to the emergence of several fatal diseases, and rising demand for personalized medicine. The increasing emphasis on drug production will drive the growth of the market in North America during the forecast period.

Market Dynamics and Customer Landscape

The market is being propelled by several key drivers and emerging trends. Firstly, the prevalence of lower respiratory tract infections, affecting both children and the geriatric population, underscores the critical need for effective pneumonia diagnostics. As microorganisms such as bacteria, viruses, fungi, and parasites continue to pose significant health risks, the demand for accurate and timely pneumonia testing solutions remains high.

Moreover, advancements in nucleic acid detection technologies, such as point-of-care (POC) testing and multiplex PCR, are revolutionizing pneumonia diagnostics. These innovative methods offer rapid and efficient detection capabilities, enabling healthcare providers to promptly identify the causative agents of pneumonia and initiate appropriate treatment strategies. The introduction of revolutionary technologies enhances efficiency and delivers rapid test results, aligning with the growing emphasis on patient-centered healthcare and immediate diagnostic interventions.

Furthermore, the increasing healthcare expenditure, coupled with initiatives led by organizations like the Clinton Health Access Initiative (CHAI) and the Centers for Disease Control and Prevention (CDC), are driving market growth. These efforts focus on improving healthcare infrastructure and promoting the adoption of advanced pneumonia testing technologies worldwide. As the prevalence of chronic diseases like asthma, bronchitis, and the common cold continues to rise, the demand for accurate and accessible pneumonia diagnostics is expected to escalate, further fueling market expansion.

Our researchers analyzed the data with 2022 as the base year and the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Market Driver

The market is experiencing notable growth driven by the escalating prevalence of pneumonia and the associated concerns regarding mortality rates. A significant surge in pneumonia cases globally is expected to fuel the demand for advanced diagnostic solutions. Pneumonia, particularly prevalent among children and the elderly, remains a leading cause of hospitalization worldwide. For instance, according to data released by the United Nations International Children's Emergency Fund (UNICEF), there were approximately 1,400 cases per 100,000 individuals globally in 2020 alone. Consequently, factors like these play pivotal roles in propelling market growth.

The market is experiencing growth due to the high prevalence of pneumonia, particularly among children and the elderly. Pneumonia, an acute lung infection caused by various pathogens such as Streptococcus, Legionella, Chlamydophilla, and Mycoplasma, is a leading cause of hospitalization for infectious diseases. According to UNICEF, there were approximately 1,400 cases per 100,000 people worldwide in 2020. The mortality rate is high, making early and accurate diagnosis essential. Advanced diagnostic products, including microscopy, culture, blood cultures, antigen detection, serology, and sensor technology, are used for detection. However, challenges such as pricing pressure, difficulty in diagnosing, false positive results, superinfection, medication complications, and physician approaches require continuous innovation. The World Health Organization emphasizes preventive care, point-of-care diagnostics, and investments in healthcare awareness and reimbursement policies to address these challenges. Chronic diseases and immunoassay approaches are also areas of focus in the market.

Furthermore, it is recognized as a leading cause of hospitalization among infectious diseases, prompting critical care and further microbiological testing for accurate diagnosis. The burden of poverty-related factors such as malnutrition, inadequate access to safe drinking water and sanitation, and exposure to air pollution contributes significantly to pneumonia-related mortality in low-resource settings. As a response to the escalating mortality rates, governments in developing countries are initiating efforts to enhance diagnostic awareness to prevent avoidable deaths. Consequently, these factors are anticipated to drive significant growth of the market research during the forecast period.

Significant Market Trends

The rising number of M&A and new product launches are emerging trends in the market. The new product additions will motivate consumers to purchase various pneumonia-testing products. Furthermore, the increasing number of product launches and M&A also increases the competition in the market, which, in turn, will lead to innovation and differentiation.

The market for advanced diagnostic products related faces unique challenges due to the complex nature of the diseases caused by pathogens such as Streptococcus, Legionella, Chlamydophilla, and Mycoplasma. Mortality rates associated with acute lung infections, including pneumonia, are significant, highlighting the importance of accurate and timely diagnoses. However, health awareness and marketing efforts play a limited role in this niche market. Instead, vendors focus on expanding distribution networks and increasing product availability to end-users. Infectious diseases like pneumonia, caused by various pathogens, can be challenging to diagnose due to the difficulty in obtaining respiratory tract specimens and the presence of false positive results, superinfections, and medication complications. Point-of-care diagnostics, such as microscopy, culture, blood cultures, antigen detection, serology, and sensor technologies, are essential for accurate diagnoses.

The World Health Organization emphasizes the importance of preventive care and early diagnosis in managing infectious diseases. Investments in research and development of advanced diagnostic products are crucial to address the pricing pressure and the difficulty in diagnosing various types of pneumonia, including viral and bacterial pneumonia. Physician approaches to diagnosing pneumonia involve a combination of clinical symptoms, imaging, and laboratory tests. Immunoassay approaches, such as those based on antigen detection and serology, are increasingly being used to improve diagnostic accuracy. Reimbursement policies and healthcare awareness also play a role in the adoption of these advanced diagnostic products. Chronic diseases, such as chronic obstructive pulmonary disease (COPD) and asthma, can increase the risk of pneumonia and further emphasize the importance of accurate and timely diagnoses. Hence, such partnerships are expected to fuel the growth of the market in focus during the forecast period.

Major Market Challenge

The lack of trained professionals is a major challenge impeding the market growth. Effective translation of diagnostics from research to application results in the correct diagnosis of diseases. Diagnosis of diseases requires extensive analysis to interpret the correct results. Therefore, clinical laboratories require trained specialists in this field. However, the presence of these specialists is scarce in diagnostic centers and hospitals worldwide. The global market is significant due to the high prevalence of acute lung infections caused by various pathogens such as Streptococcus, Legionella, Chlamydophilla, and Mycoplasma.

In developing economies, where healthcare infrastructure is poor and modern medical equipment is limited due to budget constraints, timely diagnosis and treatment of pneumonia are crucial to reduce mortality rates. During infectious disease outbreaks, such as COVID-19, the shortage of advanced diagnostic products for respiratory tract specimens, including pulse oximeters, ventilators, and BiPAP machines, can lead to false positive results, complications from medication, and superinfections. The World Health Organization emphasizes the importance of point-of-care diagnostics, preventive care, and investments in health awareness to combat the difficulty in diagnosing pneumonia and the pricing pressure on diagnostic tools. Physician approaches to diagnosing pneumonia involve microscopy, culture, blood cultures, antigen detection, serology, and sensor technology. Reimbursement policies and healthcare awareness are also critical factors influencing the market, particularly in the context of chronic diseases and immunoassay approaches.

Most rural hospitals across the world face issues such as the lack of patient volume required to justify having specialists. Furthermore, appointments of in-house specialists are cost-prohibitive, especially for small medical facilities. Limited public funds, the allocation of a small portion of this funding to laboratories, and an even smaller portion being allocated for quality assurance are some of the reasons for the lack of specialists in many developing countries. Therefore, end-users such as hospitals and diagnostic centers need to invest heavily to increase the number of trained professionals by providing training to their employees. This training and hiring of professionals increase the cost, which in turn, will hinder the market growth and trends during the forecast period.

Key Market Customer Landscape

The report includes the adoption lifecycle of the market research and growth, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market analysis and report also include key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth and forecasting strategies. 

Global Market Customer Landscape

Who are the Major Pneumonia Testing Market Companies?

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Pfizer Inc.- The company is engaged in the discovery, development, manufacturing, marketing, sales, and distribution of biopharmaceutical products worldwide. The key offerings of the company include pneumonia testing. 

The market research report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:

• Abbott Laboratories
• Acumen Diagnostics Pte Ltd.
• Becton Dickinson and Co.
• bioMerieux SA
• Bio Rad Laboratories Inc.
• Danaher Corp.
• Diamedica SIA
• Hologic Inc.
• Laboratory Corp. of America Holdings
• LGC Group
• Meridian Bioscience Inc.
• OpGen Inc.
• Quest Diagnostics Inc.
• Quidel Corp.
• Thermo Fisher Scientific Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, robust, tentative, and weak.

Segment Overview

The report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. 

• Product Type Outlook 
  • Consumables
  • Analyzers

• Method Outlook 
  • Immunodiagnostics
  • Molecular diagnostics
  • Point-of-care testing

• Region Outlook 
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
    • Others
  • Rest of World
    • Saudi Arabia
    • South Africa
    • Brazil
    • Others

Market Analyst Overview 

The market addresses the critical need for Point of care (POC) testing and accurate diagnostics in lower respiratory tract infections. Recognizing symptoms such as short breathing, fever, chest pain, nausea, and vomiting is crucial. Pneumonia often involves inflammation in the air sacs caused by various microorganisms. Advances in pneumonia diagnostics, including point-of-care (POC) testing, utilizing techniques such as enzyme-linked immunosorbent assay (ELISA), immunofluorescence, polymerase chain reaction (PCR), and immunohistochemistry (IHC), have significantly improved detection capabilities. The market's growth is influenced by rising healthcare expenditure, the development of healthcare infrastructure, and the increasing role of diagnostic laboratories. Additionally, with a shift towards home care, becomes more accessible, ensuring timely and efficient identification of respiratory infections.

Additionally,the market is witnessing significant growth driven by factors such as the rising demand due to the increasing incidence of pneumonia worldwide. As alveoli become compromised, fluids and pus accumulation occur, particularly in individuals with weakened immune systems. Various types of pathogens including bacteria, viruses, fungi, and parasites contribute to pneumonia, necessitating advanced diagnostic techniques such as nucleic acid detection and immunodiagnostics. However, challenges persist, such as the time-consuming process of traditional methods like cultures and unmet clinical needs. Nonetheless, the market is evolving with the development of newer products like pneumonia testing kits, addressing the growing prevalence of community-acquired pneumonia across both younger and geriatric populations. Additionally, reimbursement policies and the role of contract research organizations (CROs) are shaping the landscape, facilitating innovation in pneumonia diagnostics and therapeutics.

Market Scope
Report Coverage	Details
Page number	168
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 5.3%
Market growth 2023-2027	USD 709 million
Market structure	Fragmented
YoY growth 2022-2023(%)	5.13
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 32%
Key countries	US, China, Japan, Germany, and UK
Competitive landscape	Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
Key companies profiled	Abbott Laboratories, Acumen Diagnostics Pte Ltd., Becton Dickinson and Co., bioMerieux SA, Bio Rad Laboratories Inc., Danaher Corp., Diamedica SIA, Hologic Inc., Laboratory Corp. of America Holdings, LGC Group, Meridian Bioscience Inc., OpGen Inc., Pfizer Inc., Quest Diagnostics Inc., Quidel Corp., Thermo Fisher Scientific Inc., Trinity Biotech Plc, Siemens AG, F. Hoffmann La Roche Ltd., and DiaSorin SpA
Market dynamics	Parent market growth analysis, Market forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request Market Research Report Sample PDF

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the market between 2023 and 2027
• Precise estimation of the size of the market size and its contribution to the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the industry across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of the market companies

We can help! Our analysts can customize this market reserach report to meet your requirements. Get in touch